Regular screening was statistically significantly related to a higher likelihood of screen-detection cancers overall with OR: 1.28 (95%CI: 1.18–1.40) and for breast cancer of luminal, luminal-HER2-positive, TNBC, and unknown molecular subtype with OR: 1.21 (95%CI: 1.09–1.34), OR: 1.79 (95%CI: 1.38–2.33), OR: 1.62 (95%CI: 1.10–2.41), and OR: 1.37 (95%CI: 1.05–1.81), respectively (Table 4). Here, ERBB2 is linked to cancer.